Thu, Aug 21, 2014, 8:47 AM EDT - U.S. Markets open in 43 mins.

Recent

% | $
Quotes you view appear here for quick access.

Novartis AG Message Board

  • bluecheese4u bluecheese4u Oct 25, 2012 1:58 AM Flag

    Novartis Third quarter 2012 results

    Novartis Third quarter 2012 results

    Recently launched products support Novartis sales in third quarter, offsetting
    patent expiry; Pharmaceuticals well-positioned with further pipeline progress
     Group net sales declined 2% in constant currencies (cc) in the third quarter, down 1% over
    nine months
    o Third quarter net sales reached USD 13.8 billion (-7%, -2% cc); nine months net sales were USD
    41.8 billion (-4%, -1% cc)
    o Core1 operating income was USD 3.9 billion (-5%, -3% cc) in third quarter, USD 11.5 billion
    (-7%, -4% cc) in nine months; operating income reached USD 3.0 billion (+3%, +5% cc) in the
    third quarter and USD 9.0 billion (-7%, -4% cc) for the nine months
    o Core EPS was USD 1.34 (-8%, -6% cc) in third quarter, USD 3.98 (-8%, -5% cc) in nine months;
    EPS was USD 1.01 (-1%, +2% cc) in third quarter and USD 3.09 (-7%, -4% cc) in nine months
    o Free cash flow1 reached USD 3.5 billion for third quarter (2011 USD 3.7 billion); USD 7.9 billion
    in nine months (2011 USD 8.6 billion)
     Strong flow of innovation news continues; respiratory portfolio prospects significantly
    advanced with QVA149 EU filing
    o Eight regulatory milestones in Pharmaceuticals, including Afinitor FDA and EMA approval in
    advanced breast cancer, Jakavi EMA approval in myelofibrosis and Seebri Breezhaler EMA
    approval in COPD
    o Respiratory portfolio progressed with strong Phase III trials of QVA149 leading to filing in the EU
     Recently launched products in Pharmaceuticals totaled USD 2.8 billion and represented 36%
    of net sales (USD 8.3 billion and 35% of net sales for nine months); Pharmaceuticals wellpositioned
    to emerge from Diovan patent expiry
     Quality remediation continues to be actively addressed; first Consumer Health products
    resupplied in the US from third party sources
     2012 Group performance outlook reaffirmed
    Key figures

    novartis

    Novartis Q3 and 9M 2012 Interim Financial Report – Supplementary Data

    novartis

    URLs at talkstock

 
NVS
88.60+0.24(+0.27%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.